SAN DIEGO, April 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health. The report details Illumina's role as a champion for patients, communities, people, and the planet.

"Over the last year, we saw countless examples of resilience, perseverance, and progress as we continue to respond to the pandemic, push for greater access to and equity in genomics, and protect our planet," said Francis de Souza, Chief Executive Officer. "Through our advanced technology, we empower researchers and clinicians to find solutions for the world's most pressing challenges. As we look forward, we are focused on continuing to positively impact the world by unlocking the power of the genome to shape a more sustainable, more equitable, and healthier future for all."

Illumina's ESG efforts outlined in the Report include the following focus areas:

• 扩大对基因组学的访问
• Empowering our communities
• 整合环境可持续性金博宝怎么注册
• 养育我们的人民
• Operating responsibly and enabling innovation for good

In 2021, the company took significant steps to advance each of these areas, including:

• Achieved 1 billion covered lives for genomic testing around the world
• 全球总捐款总额超过1,300美元以上，捐款超过1,300美元
• Sourced 59% of global electricity consumption from renewable sources
• 直接操作的范围1和2减少了24％
• Committed to net zero emissions throughout entire value chain by 2050
• Maintained a zero net pay gap
• Increased female representation in executive leadership by 5% in the last 3 years
• Reached 50% minority representation in the US workforce
• Engaged over 4,000 employees in employee resource group (ERG) programming.

Read the full report on Illumina's金博宝手机版网页CSR网站.

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visitwww.illumina.comand connect with us onTwitter,Facebook,LinkedIn,Instagram, andYouTube.

Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com

媒体：
Adi Raval
202.629.8172
ILMN-PR@illumina.com